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Abstract. Adipokines resistin and lipokalin-2 and its role in the pathogenesis of polycystic ovary syndrome and 
metabolic syndrome. Voronenko N.Yu. Adipose tissues hormones resistin and lipocalin -2 play an important role in 
the regulation of lipid and carbohydrate metabolism, inflammation and immune disorders, fertility and reproductive 
mechanisms. Obesity and overweight are significantly involved in the process of fertility decline. Women with obesity 
and metabolic syndrome have abnormal adypokine plasma levels. The aim of the study was to investigate the 
relationships between the women’s of the hypothalamic-pituitary-ovarian axis and energy metabolism. Methods: basal 
levels of resistin, lipocalin-2, follicular stimulating, luteinizing hormones, estradiol, total and free testosterone, 
dihydrotestosterone, dihydroepiandrosteron sulfate, androstenedione, cortisol, anti-mullerian hormone, prolactin, 
insulin, folistatin, homocysteine, interleukin-6 and sex-binding globulin were determined in the serum of 35 women of 
reproductive age with metabolic syndrome (MS), 33 patients of reproductive age with polycystic ovary syndrome 
(PCOS) and in 54 healthy contols. It is found that despite the normal values of hormones lipocalin-2 and resistin even 
in patients with obesity, their concentrations significantly correlated with anthropometric, hormonal and metabolic 
parameters. We established statistically significant stimulatory effects of lipocalin-2 and resistin on the synthesis of 
ovarian steroids and the significant inhibitory effect of lipocalin-2 and resistin on ovarian and adrenal androgens 
synthesis in normal physical condition and reproductive health. In MS and PCOS these relationships are not 
established. The results obtained allow us to propose the assumption of the existence of metabolic changes of the 
sensitivity of the reproductive system and the adrenal gland to the effects of lipocalin -2 and resistin in women with 
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:   F(2;119) = 1,8976; p = 0,1544
 -  95% 
. 1. ,  M
 1  
(n=33) (n=35) (n=54) 
- - -
, / 2 26,11 2,26 36,21 3,66 22,99 2,84 <0,001 <0,001 <0,001 
, 78,43 6,71 105,78 10,70 69,66 8,70 <0,001 <0,001 <0,001 
-2, ng/ml 30,0 16,7 36,1 25,4 36,1 25,4 0,98 0,134 0,223 
, ng/ml 5,7 3,5 5,5 2,5 6,7 3,0 0,074 0,168 0,757 
, IU/mL 13,8 8,7 23,5 11,3 15,3 8,1 0,001 0,417 0,001 
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 ( )
 = 15,117 - 1,145  * _6
 r = -0,3456










. 2. ’ -6 
 2  
M r(X,Y) R2 p
 5.54 2.55    
 36.21 3.66 0.091 0.008 0.603 
 105.78 10.70 0.089 0.008 0.611 
-  2.38 1.43 0.039 0.002 0.824 
 533.57 431.87 -0.252 0.063 0.145 
 23.51 11.38 -0.205 0.042 0.238 
 7.84 3.51 0.140 0.020 0.422 
 9.41 3.98 -0.025 0.001 0.885 
 1032.39 345.27 0.132 0.017 0.451 
 182.29 105.13 -0.081 0.007 0.644 
 8.60 6.23 0.051 0.003 0.771 
 7.80 3.74 0.087 0.008 0.620 
 12.60 7.14 0.014 0.001 0.935 
 1.84 1.02 0.154 0.024 0.377 
 0.47 0.38 -0.220 0.048 0.205 
 4.82 4.63 -0.189 0.036 0.277 
 5.72 2.38 -0.284 0.081 0.098 
 78.91 64.16 0.247 0.061 0.153 
 36.07 25.41 -0.109 0.012 0.532 
 10.68 11.48 -0.143 0.021 0.412 
- `  4 49.79 16.63 0.174 0.030 0.317 
 12.68 6.67 0.117 0.014 0.503 
 2258.86 518.69 -0.298 0.089 0.082 
-6 8.37 0.77 -0.346 0.119 0.042 
:  – ,  – , r (X,Y) – , R2 – 
,  - .
100
 ( . 1, . 1) 
,
 (5,7 3,5 ng/ml, 
6,7 3,0 ng/ml  5,5 2,5 ng/ml ; - =
0,074, -  =0,168, - =0,749). -
’ -
-
 ( . 3), 
 3  4, 
’ -
 (r=0,4090, =0,018), 
(r=0,3585, =0,041). 
 3  
M r(X,Y) R2 p
 5.66 3.51 - - - 
 26,11 2,26 0.079 0.006 0.660 
 78,43 6,71 0.091 0.008 0.614 
-  2.32 1.02 -0.085 0.007 0.638 
 482.58 427.53 0.016 0.000 0.932 
 13.86 8.73 0.090 0.008 0.618 
 10.14 5.70 -0.150 0.023 0.404 
 8.95 3.88 0.151 0.023 0.402 
 470.08 274.20 0.409 0.167 0.018 
 191.97 112.31 -0.229 0.052 0.200 
 13.62 9.21 0.112 0.012 0.536 
 8.85 4.27 -0.096 0.009 0.593 
 9.89 4.07 -0.099 0.010 0.585 
 1.05 0.81 0.060 0.004 0.740 
 0.29 0.22 0.121 0.015 0.504 
 3.30 3.20 0.358 0.128 0.041 
 6.91 1.36 -0.012 0.000 0.946 
 127.39 78.50 0.007 0.000 0.970 
 30.00 16.76 0.153 0.023 0.396 
 6.38 5.45 0.085 0.007 0.638 
- `  4 50.88 13.62 -0.105 0.011 0.562 
 17.44 10.07 -0.067 0.004 0.711 
 1998.48 550.35 0.178 0.032 0.321 
-6 8.21 0.82 0.101 0.010 0.577 
:  – ,  – , r (X,Y) – , R2 – 
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 = 4,3690 + 0,39232 * 
r = 0,35847













 4  
M r(X,Y) R2 p
 6.82 3.11    
 22,99 2,84 -0.210 0.044 0.166 
 69,66 8,70 -0.190 0.036 0.212 
-  2.45 1.03 -0.437 0.191 0.003 
 403.04 111.06 -0.403 0.162 0.006 
 16.00 8.51 -0.139 0.019 0.363 
 5.79 3.73 -0.295 0.087 0.049 
 9.81 3.15 0.054 0.003 0.725 
 583,5 379,2 0.055 0.003 0.719 
 189.94 100.66 -0.132 0.017 0.389 
 12.02 7.31 -0.115 0.013 0.451 
 8.73 3.50 -0.105 0.011 0.492 
 11.00 4.64 -0.140 0.020 0.360 
 0.22 0.09 0.158 0.025 0.301 
 0.32 0.19 0.334 0.112 0.025 
 3.13 3.41 0.441 0.195 0.002 
 3.00 1.26 -0.415 0.173 0.005 
 107.93 82.87 0.352 0.124 0.018 
 36.71 20.88 0.584 0.341 0.000 
 5.88 5.43 -0.063 0.004 0.679 
- `  4 52.58 19.08 0.020 0.000 0.895 
 16.45 8.43 0.128 0.016 0.401 
 2126.01 562.68 -0.162 0.026 0.287 
-6 8.47 0.97 -0.322 0.104 0.031 
:  – ,  – , r (X,Y) – , R2 – 
,  - 
,






 ( . 4) 
’
 (r=0,3344, 






-2 ( . 1, . 5) 
,
 (36,1 25,4 ng/ml, 30,0 16,7 
ng/ml  36,1 25,4 ng/ml ; - = 0,98, 
-  =0,168, - =0,223).












:   F(2;119) = 0,9691; p = 0,3824
. 5. ,  M
’ -2
( . 5, . 6, 7) -
’ ,
’ -2




 5  
M r(X,Y) R2 p
 36.07 25.41 - - - 
 36.21 3.66 -0.128 0.016 0.464 
 105.78 10.70 -0.187 0.035 0.283 
-  2.38 1.43 -0.384 0.147 0.023 
 533.57 431.87 -0.119 0.014 0.494 
 23.51 11.38 -0.257 0.066 0.136 
 7.84 3.51 -0.116 0.013 0.508 
 9.41 3.98 -0.122 0.015 0.485 
 1032.39 345.27 -0.057 0.003 0.746 
 182.29 105.13 0.054 0.003 0.756 
 8.60 6.23 -0.029 0.001 0.868 
 7.80 3.74 -0.062 0.004 0.722 
 12.60 7.14 -0.308 0.095 0.071 
 1.84 1.02 0.060 0.004 0.733 
 0.47 0.38 -0.042 0.002 0.811 
 4.82 4.63 -0.031 0.001 0.862 
 5.72 2.38 -0.216 0.047 0.212 
 78.91 64.16 -0.184 0.034 0.291 
 10.68 11.48 -0.334 0.112 0.050 
- `  4 49.79 16.63 0.040 0.002 0.820 
 12.68 6.67 0.059 0.004 0.736 
 5.54 2.55 -0.109 0.012 0.532 
 2258.86 518.69 -0.103 0.011 0.555 
-6 8.37 0.77 -0.143 0.020 0.413 
:  – ,  – , r (X,Y) – , R2 – 
,  - .
104
 ( )
 = 52,333 - 6,831  * 
r = - 0,3838
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 ( . 6). 
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 = 43,973 - 0,7403  * 
r = - 0,3344
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 6  
M r(X,Y) R2 p
 30.00 16.76 - - - 
 26,11 2,26 -0.209 0.044 0.243 
 78,43 6,71 -0.187 0.035 0.297 
-  2.32 1.02 -0.120 0.014 0.506
 482.58 427.53 -0.198 0.039 0.268 
 13.86 8.73 0.127 0.016 0.482 
 10.14 5.70 -0.258 0.067 0.147 
 8.95 3.88 0.016 0.000 0.931 
 148.95 3.88 0.016 0.000 0.931 
 191.97 112.31 -0.022 0.000 0.902 
 13.62 9.21 0.042 0.002 0.817 
 8.85 4.27 0.064 0.004 0.724 
 9.89 4.07 0.010 0.000 0.957 
 1.05 0.81 -0.330 0.109 0.061 
 0.29 0.22 -0.248 0.062 0.163 
 3.30 3.20 -0.151 0.023 0.402 
 6.91 1.36 -0.277 0.077 0.119 
 127.39 78.50 0.135 0.018 0.455 
 6.38 5.45 -0.288 0.083 0.104
- `  4 50.88 13.62 0.105 0.011 0.563 
 17.44 10.07 0.214 0.046 0.233 
 5.66 3.51 0.153 0.023 0.396 
 1998.48 550.35 0.300 0.090 0.089 
-6 8.21 0.82 -0.110 0.012 0.543 
:  – ,  – , r (X,Y) – , R2 – 




 ( . 7) 
’ -
-2 -  (r=-0,2959, =0,048), -
 (r=-0,3002, =0,045),  (r=-0,3270, 
=0,028)  (r=-0,4332, 
=0,003), -6 (r=-0,3289, =0,027). 
-2 -
 ( . 7). , -
-
’
-2  (r=0,4326, =0,028) 











,  (r=0,5840, 
=0,0001). 
,  ( .
1) ’ , -2
106
 ( -2: 
36,1 25,4 ng/ml, 30,0 16,7 ng/ml  36,1 25,4 ng/ml 
; - = 0,98, -  =0,134, - =0,223; -
: 5,5 2,5 ng/ml, 5,7 3,5 ng/ml  6,7 3,0 ng/ml 
; - = 0,074, -  =0,168, - =0,757).
 ( . 1) 








 7  
M r(X,Y) R2 p
 36.71 20.88    
 22,99 2,84 -0.197 0.039 0.194 
 69,66 8,70 -0.188 0.035 0.216 
-  2.45 1.03 -0.296 0.088 0.048 
 403.04 111.06 -0.300 0.090 0.045 
 16.00 8.51 -0.166 0.027 0.277 
 5.79 3.73 -0.058 0.003 0.706 
 9.81 3.15 0.132 0.017 0.388 
 583,5 379,2 0.061 0.004 0.692 
 189.94 100.66 -0.006 0.000 0.970 
 12.02 7.31 -0.172 0.029 0.260 
 8.73 3.50 -0.146 0.021 0.339 
 11.00 4.64 0.019 0.000 0.903 
 0.22 0.09 -0.074 0.005 0.631 
 0.32 0.19 0.433 0.187 0.003 
 3.13 3.41 0.328 0.108 0.028 
 3.00 1.26 -0.433 0.188 0.003 
 107.93 82.87 0.194 0.038 0.201 
 5.88 5.43 -0.134 0.018 0.381 
- `  4 52.58 19.08 -0.209 0.044 0.168 
 16.45 8.43 -0.039 0.002 0.797 
 6.82 3.11 0.584 0.341 0.000 
 2126.01 562.68 0.156 0.024 0.305 
-6 8.47 0.97 -0.329 0.108 0.027 
:  – ,  – , r (X,Y) – , R2 – 
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